References
- 1. M. Lunder, M. Janić, B. Jug and M. Šabovič, The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial, Eur. J. Intern. Med. 23 (2012) 261-266; https://doi.org/10.1016/j.ejim.2011.11.011
- 2. V. Savić, B. Eržen, M. Janić, M. Lunder, M. Boncelj, K. Kanc, A. Janež and M. Šabovič, Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients, Diab. Vasc. Dis. Res. 10 (2013) 420-425; https://doi.org/10.1177/1479164113485102
- 3. M. Janić, M. Lunder, M. Prezelj and M. Šabovič, A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males, J. Cardiopulm. Rehabil. Prev. 34 (2014) 208-212; https://doi.org/10.1097/HCR.0000000000000027
- 4. R. C. Hermida, C. Calvo, D. E. Ayala and J. E. Lopez, OR-6: Administration time-dependent efficacy of valsartan-atorvastatin combination in hyperlipidemic patients with essential hypertension, Am. J. Hypertens. 18 (S4) (2005) 2A; https://doi.org/10.1016/j.amjhyper.2005.03.006
- 5. S. A. Hussein, H. M. El-Wadood, M. A. Abdallah and A. A. Khorshed, HPTLC with fluorescence densitometry for simultaneous determination of some angiotensin II receptor blockers in tablets and plasma, J. AOAC Int. 98 (2015) 354-360; https://doi.org/10.5740/jaoacint.14-179
- 6. D. Tsvetkova, D. Obreshkova and S. Ognjanov, Validation of TLC densitometry for simultaneous quality and quantity analysis of angiotensin II receptor antagonist losartan, telmisartan and valsartan, Chim. Pharm. 64 (2011) 39-44.
- 7. T. Inglot, A. Gumieniczek, L. Komsta and A. Kasinska, LC and principal component analysis in the lipophilicity study of seven angiotensin II-AT1 receptor antagonists (sartans), Chromatographia 68 (2008) 977-983; https://doi.org/10.1365/s10337-008-0801-5
- 8. J. Golubovic, A. Protic, B. Otasevic and M. Zecevic, Quantitative structure-retention relationships applied to development of liquid chromatography gradient-elution method for the separation of sartans, Talanta 150 (2016) 190-197; https://doi.org/10.1016/j.talanta.2015.12.035
- 9. K. C. Skai and A. P. Mazureki, Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method, Acta Pol. Pharm. Drug Res. 68 (2011) 831-837.
- 10. S. Hillaert and W. V. den Bossche, Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-II-receptor antagonists. J. Chromatogr. A 979 (2002) 323-333; https://doi.org/10.1016/S0021-9673(02)01247-5
- 11. S. Hillaert, T. R. M. De Beer, J. O. De Beer and W. V. den Bossche, Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists, J. Chromatogr. A 984 (2003) 135-146; https://doi.org/10.1016/S0021-9673(02)01832-0
- 12. S. Zargar and T. A. Wani, New UPLC-MS/MS method for simultaneous determination of telmisartan and hydrochlorthiazide in human plasma, Lat. Am. J. Pharm. 33 (2014) 432-440.
- 13. E. Şatana, S. Altinay, N. G. Göger, S. A. Özkan and Z. Şentürk, Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC, J. Pharm. Biomed. Anal. 25 (2001) 1009-1013; https://doi.org/10.1016/S0731-7085(01)00394-6
- 14. M. M. Deshpande, M. P. Mahajan and S. D. Sawant, Simultaneous estimation of valsartan and hydrochlorothiazide in fixed dose combination in UV spectrophotometry, Int. J. Pharm. Sci. Res. 3 (2012) 236-240.
- 15. T. A. Wani, A. Ahmad, S. Zargar, N. Y. Khalil and I. A. Darwish, Use of response surface methodology for development of new microwell-based spectrophotometric method for determination of atorvastatin calcium in tablets, Chem. Cent. J. 6 (2012) 134-142; https://doi.org/10.1186/1752-153X-6-134
- 16. I. Muszalska, A. Sobczak, A. Dołhaand and A. Jelińska, Analysis of sartans: A review, J. Pharm. Sci. 103 (2014) 2-28; https://doi.org/10.1002/jps.23760
- 17. M. S. Tahir, A. Adnan and Q. Syed, Chromatographic resolution of angiotensin II receptor antagonists (sartans), J. Chromatogr. B 1027 (2016) 57-63; https://doi.org/10.1016/j.jchromb. 2016.05.023
- 18. A. Nakashima, C. Saxer, M. Niina, N. Masuda, K. Iwasaki and K. Furukawa, Determination of fluvastatin and its five metabolites in human plasma using simple gradient reversed-phase highperformance liquid chromatography with ultra-violet detection, J. Chromatogr. B 760 (2001) 17-25; https://doi.org/10.1016/S0378-4347(01)00250-X
- 19. F. P. Gomes, P. L. Garcia, J. M. P. Alves, A. K. Singh, E. R. M. Kedor-Hackmann and M. I. R. M. Santoro, Development and validation of stability-indicating HPLC methods for quantitative determination of pravastatin, fluvastatin, atorvastatin and rosuvastatin in pharmaceuticals, Anal. Lett. 42 (2009) 1784-1804; https://doi.org/10.1080/00032710903060669
- 20. E. Kublin, E. Malanowicz, B. Kaczmarska-Graczyk, K. Czerwińska, E. Wyszomirska and A. P. Mazurek, Development of chromatographic method for determination of drugs reducing cholesterol level - statins and ezetimibe, Acta Pol. Pharm. Drug Res. 72 (2015) 429-437.
- 21. J. L. Yan, Determination of fluvastatin sodium by differential pulse voltammetry, Pak. J. Biol. Sci. 9 (2006) 2156-2158.
- 22. M. P. S. Neves, P. A. Nouws and C. Delerue-Matos, Direct electroanalytical determination of fluvastatin in a pharmaceutical dosage form: Batch and flow analysis, Anal. Lett. 41 (2008) 2794-2804; https://doi.org/10.1080/00032710802421889
- 23. G. Ergin, S. Çağlar, A. Önal and S. E. Toker, Spectrophotometric determination of 3-hydroxy-3- methylglutaryl coenzyme-A reductase inhibitors in pharmaceutical preparations, Turk. J. Chem. 37 (2013) 171-181.
- 24. K. Pasha, S. Muzeeb, S. J. S. Basha, D. Shashikumar, R. Mullangi and N. R. Srinivas, Analysis of five HMG-CoA reductase inhibitors - atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies, Biomed. Chromatogr. 20 (2006) 282-293; https://doi.org/10.1002/bmc.561
- 25. S. Ertürk, A. Önal and S. M. Çetin, Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples, J. Chromatogr. B. 793 (2003) 193-205; https://doi.org/10.1016/S1570-0232(03)00314-3
- 26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Geneva November 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access date April 22, 2017.
- 27. Polish Pharmacopoeia, Xth ed., Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warszawa 2016.